Astra goes subcutaneous in its Merck race
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
Pfizer tries to banish the ghost of Celldex
A son of glembatumumab vedotin has just started its phase 1 study.
A tale of two biotechs
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Nurix pushes its degrader forward
The company will start its confirmatory bexobrutideg study in June.
Ideaya’s darovasertib plan comes together
Optimum-02 virtually replicates phase 1, and a filing will follow.
Replimune’s fight with the FDA deepens
The oncolytic virus vuso-vec is slapped with its second CRL.
Allogene finds a way forward for allogeneic Car-T
After setbacks, cema-cel might have a path to approval in lymphoma.
